Clinical Trial Update: Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor

View source ↗

Summary

This study analyzes data from the EBMT registry on patients receiving plerixafor, summarizing outcomes in lymphoma and multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma

Drugs mentioned

• Mozobil (plerixafor)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Lymphoma, Multiple Myeloma | Status: COMPLETED